Loading clinical trials...
Loading clinical trials...
Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare
Conditions
Interventions
Rituximab
Locations
1
United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Start Date
June 1, 2016
Primary Completion Date
January 31, 2022
Completion Date
January 31, 2022
Last Updated
July 27, 2023
NCT06978647
NCT07212322
NCT04871191
NCT05988008
Lead Sponsor
Massachusetts General Hospital
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions